Nitrofurantoin
Furadantin, Ivadantin, Macrobid, Macrocrystalline, Macrodantin, Nitrofurantoin, Nitrofurantoin Nitrofurantoin (nitrofurantoin) is a small molecule pharmaceutical. Nitrofurantoin was first approved as Furadantin on 1982-01-01. It is used to treat bacterial infections, escherichia coli infections, klebsiella infections, staphylococcal infections, and urinary tract infections in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| urogenital diseases | D000091642 |
Trade Name
FDA
EMA
Furadantin, Macrodantin, Nitrofurantoin (discontinued: Furadantin, Furalan, Ivadantin, Nitrofurantoin, Nitrofurantoin macrocrystalline)
CombinationsMacrobid, Nitrofurantoin (monohydrate/macrocrystals) (discontinued: Nitrofurantoin (monohydrate/macrocrystals))
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Nitrofurantoin
+
Nitrofurantoin
+
macrocrystalline
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| MACROBID | Almatica Pharma | N-020064 RX | 1991-12-24 | 1 products, RLD, RS |
Nitrofurantoin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| FURADANTIN | Casper Pharma | N-009175 RX | 1982-01-01 | 2 products, RLD |
Show 1 discontinued
Nitrofurantoin sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| IVADANTIN | Procter And Gamble | N-012402 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Nitrofurantoin
+
macrocrystalline
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| MACRODANTIN | Almatica Pharma | N-016620 RX | 1982-01-01 | 3 products, RLD |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| furadantin | New Drug Application | 2024-03-28 |
| macrobid | New Drug Application | 2023-06-30 |
| macrodantin | New Drug Application | 2023-06-01 |
| nitrofurantion macrocrystals | New Drug Application | 2018-06-05 |
| nitrofurantoin | ANDA | 2024-10-30 |
| nitrofurantoin (macrocrystals) | ANDA | 2024-10-15 |
| nitrofurantoin (monohydrate/macrocrystals) | ANDA | 2024-10-22 |
| nitrofurantoin macrocrystals | ANDA | 2024-09-13 |
| nitrofurantoin mono | New Drug Application | 2022-10-09 |
| nitrofurantoin monohydrate macrocrystalline | New Drug Application | 2020-12-14 |
Show 4 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
71 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | 2 | 4 | 4 | 21 | 8 | 39 |
| Infections | D007239 | EFO_0000544 | — | 2 | 1 | 4 | 14 | 8 | 29 |
| Communicable diseases | D003141 | — | — | 1 | 1 | 4 | 11 | 3 | 20 |
| Cystitis | D003556 | EFO_1000025 | N30 | — | 3 | 2 | 6 | — | 11 |
| Nephrolithiasis | D053040 | — | N20.0 | — | — | 1 | 2 | 1 | 4 |
| Kidney calculi | D007669 | EFO_0004253 | N20 | — | — | 1 | 2 | 1 | 4 |
| Recurrence | D012008 | — | — | — | — | — | 4 | — | 4 |
| Bacteriuria | D001437 | — | R82.71 | — | — | — | 1 | 3 | 4 |
| Overactive urinary bladder | D053201 | EFO_1000781 | N32.81 | — | — | — | 3 | — | 3 |
| Pyelonephritis | D011704 | EFO_1001141 | N10-N16 | — | — | 1 | 2 | — | 3 |
Show 18 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | 1 | 1 | — | — | 2 |
| Chronic renal insufficiency | D051436 | — | N18 | — | — | 1 | — | — | 1 |
| Congenital abnormalities | D000013 | EFO_0003915 | Q89.9 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Kidney transplantation | D016030 | — | — | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 3 | — | — | — | 1 | 4 |
| Osteomyelitis | D010019 | EFO_0003102 | M86 | 1 | — | — | — | — | 1 |
| Urinary diversion | D014547 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sepsis | D018805 | HP_0100806 | A41.9 | — | — | — | — | 2 | 2 |
| Wounds and injuries | D014947 | — | T14.8 | — | — | — | — | 1 | 1 |
| Chemical and drug induced liver injury | D056486 | EFO_0004228 | — | — | — | — | — | 1 | 1 |
| Asymptomatic infections | D058345 | — | — | — | — | — | — | 1 | 1 |
| Hypospadias | D007021 | EFO_0004209 | Q54 | — | — | — | — | 1 | 1 |
| Asymptomatic diseases | D058070 | — | — | — | — | — | — | 1 | 1 |
| Urolithiasis | D052878 | — | N20-N23 | — | — | — | — | 1 | 1 |
| Hematuria | D006417 | HP_0000790 | R31 | — | — | — | — | 1 | 1 |
| Menstruation disturbances | D008599 | HP_0400007 | N91.5 | — | — | — | — | 1 | 1 |
| Metaplasia | D008679 | — | — | — | — | — | — | 1 | 1 |
Show 5 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Nitrofurantoin |
| INN | nitrofurantoin |
| Description | Nitrofurantoin is an imidazolidine-2,4-dione that is hydantoin substituted at position 1 by a [(5-nitro-2-furyl)methylene]amino group. An antibiotic that damages bacterial DNA. It has a role as a hepatotoxic agent, an antiinfective agent and an antibacterial drug. It is an organonitrogen heterocyclic antibiotic, an organooxygen heterocyclic antibiotic, a nitrofuran antibiotic and an imidazolidine-2,4-dione. It is functionally related to a semicarbazide. |
| Classification | Small molecule |
| Drug class | antiepileptics (hydantoin derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C1CN(/N=C/c2ccc([N+](=O)[O-])o2)C(=O)N1 |
Identifiers
| PDB | — |
| CAS-ID | 67-20-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL572 |
| ChEBI ID | 71415 |
| PubChem CID | 6604200 |
| DrugBank | DB00698 |
| UNII ID | 927AH8112L (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Nitrofurantoin – RVL Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Nitrofurantoin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 13,162 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
8,032 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use